Investigation of interindividual factors determining the pain relief and adverse effects of opioid analgesics in cancer cachexia

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460194
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: NAITO TAKAFUMI 浜松医科大学, 医学部附属病院, 副薬剤部長 (80422749)
• Research Collaborator: SATO Hikaru 浜松医科大学, 医学部附属病院, 薬剤師 ; ISHIDA Takuya 浜松医科大学, 医学部附属病院, 薬剤師
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 悪液質 / オピオイド / オキシコドン / サイトカイン / 中枢症状 / 薬物動態 / 有害作用 / がん性疼痛

Outline of Final Research Achievements

Patients with cachectic cancer experience central symptoms that include depression, somnolence, and delirium. These symptoms may be associated with elevated proinflammatory cytokines or drug treatments such as opioid analgesics. Elevated serum proinflammatory cytokines are associated with the reduction of cytochrome P450 enzymes activity. To date, the relationships between opioid pharmacokinetics, central symptoms, and serum proinflammatory cytokines have not been fully clarified at each cachexia stage. This study aimed to evaluate the oxycodone pharmacokinetics, central symptoms, and serum proinflammatory cytokines based on cachexia stage in cancer patients.

Free Research Field

臨床薬物動態学